PharmaEssentia Corporation (TPE:6446)
536.00
+6.00 (1.13%)
Apr 2, 2025, 1:30 PM CST
PharmaEssentia Revenue
In the year 2024, PharmaEssentia had annual revenue of 9.73B TWD with 90.67% growth. PharmaEssentia had revenue of 3.06B in the quarter ending December 31, 2024, with 85.90% growth.
Revenue
9.73B
Revenue Growth
+90.67%
P/S Ratio
18.03
Revenue / Employee
74.31M
Employees
131
Market Cap
176.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
Dec 31, 2020 | 557.26M | 251.57M | 82.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.43M |
Bora Pharmaceuticals Co., LTD. | 19.25B |
Lotus Pharmaceutical | 18.58B |
Oneness Biotech | 117.93M |
Lumosa Therapeutics | 39.15M |
Pegavision | 6.82B |
Polaris Group | 107.00M |
Center Laboratories | 1.62B |
PharmaEssentia News
- 6 weeks ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga